Intracerebral metastases: Difference between revisions

Jump to navigation Jump to search
Line 75: Line 75:
<gallery>
<gallery>
Image:Melanoma met.jpg|Melanoma met
Image:Melanoma met.jpg|Melanoma met
Image:Bull's eye met.jpg|Bull's eye met
</gallery>
</gallery>



Revision as of 18:26, 10 January 2009

Intracerebral metastases

WikiDoc Resources for Intracerebral metastases

Articles

Most recent articles on Intracerebral metastases

Most cited articles on Intracerebral metastases

Review articles on Intracerebral metastases

Articles on Intracerebral metastases in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Intracerebral metastases

Images of Intracerebral metastases

Photos of Intracerebral metastases

Podcasts & MP3s on Intracerebral metastases

Videos on Intracerebral metastases

Evidence Based Medicine

Cochrane Collaboration on Intracerebral metastases

Bandolier on Intracerebral metastases

TRIP on Intracerebral metastases

Clinical Trials

Ongoing Trials on Intracerebral metastases at Clinical Trials.gov

Trial results on Intracerebral metastases

Clinical Trials on Intracerebral metastases at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Intracerebral metastases

NICE Guidance on Intracerebral metastases

NHS PRODIGY Guidance

FDA on Intracerebral metastases

CDC on Intracerebral metastases

Books

Books on Intracerebral metastases

News

Intracerebral metastases in the news

Be alerted to news on Intracerebral metastases

News trends on Intracerebral metastases

Commentary

Blogs on Intracerebral metastases

Definitions

Definitions of Intracerebral metastases

Patient Resources / Community

Patient resources on Intracerebral metastases

Discussion groups on Intracerebral metastases

Patient Handouts on Intracerebral metastases

Directions to Hospitals Treating Intracerebral metastases

Risk calculators and risk factors for Intracerebral metastases

Healthcare Provider Resources

Symptoms of Intracerebral metastases

Causes & Risk Factors for Intracerebral metastases

Diagnostic studies for Intracerebral metastases

Treatment of Intracerebral metastases

Continuing Medical Education (CME)

CME Programs on Intracerebral metastases

International

Intracerebral metastases en Espanol

Intracerebral metastases en Francais

Business

Intracerebral metastases in the Marketplace

Patents on Intracerebral metastases

Experimental / Informatics

List of terms related to Intracerebral metastases

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Intracerebral metastasis accounts for approximately 25-50% of intracranial tumors in hospitalized patients. The true incidence of brain metastasis is unknown, but recent estimates are as high as 200,000 cases per year in the United States alone. 80% of brain metastases can be accounted for by five primary tumor sites: lung, breast, skin (melanoma), kidney and the gastrointestinal tract. A population-based study of 169,444 cancer patients from 1973 to 2001 in Detroit revealed that overall, 10% of patients diagnosed with one of these five primaries went on to develop brain metastases. Specifically, 19.9% of lung cancers, 6.9% of melanomas, 6.5% of renal cancers, 5.1% of breast cancers and 1.8% of colorectal cancers metastasized to the brain.

Parenchymal blood flow is an important determinant of the distribution of metastases. 80% of metastases localize to the cerebral hemispheres, 15% localize to the cerebellum and 3% localize to the basal ganglia. Often these tumors can be found at the gray/white matter junction.

Gross appearance

Typically metastases are sharply demarcated from the surrounding parenchyme and usually there is a zone of peritumoral edema out of proportion with the tumor size.

Microappearance

Typically well-demarcated with the exception of melanoma metastases.

Radiographic findings

There is a great deal of variability in the appearance of these tumors, however some generalizations can be made.

CT

NECT: Iso to hypodense mass with anywhere from zero to marked peritumoral edema.

CECT: enhancement is also variable and can be intense, punctuate, nodular or ring-enhanced if the tumour has out grown it's blood supply.

MRI

T1W: Typically iso to hypointense mass, however melanoma metastases are an exception to this rule (hyperintense due to the paramagnetic properties of melanin).

T2W: Typically hyperintense. If metastases are scattered the pattern may mimic vascular disease.

FLAIR: Typically hyperintense with hyperintense peritumoral edema.

T1 C+: The enhancement pattern can be uniform, punctuate, or ring-enhanced, but it is usually intense. Delayed sequences may show additional lesions, therefore contrast-enhance MR is the current standard for small met detection.

MRS: Intratumoral choline peak with no choline elevation in the peritumoral edema. Any tumor necrosis results in a lipid peak.

DWI: edema is out of proportion with tumour size and appears dark on trace-weighted DWI. Nuclear medicine

FDG PET: Generally considered the best imaging tool for metastases. However it can only detect metastases up to 1.5 cm in size, therefore CEMR is the gold standard to rule out small mets. Lung, breast, colorectal, head and neck, melanoma and thyroid mets are usually hypermetabolic. Mucinous adenocarcinoma and RCC are typically hypometabolic and gliomas and lymphomas are variable. Any central hypometabolism indicates necrosis.

Clinical presentation and prognosis

These patients commonly present with headache, seizure, mental status changes, ataxia, nausea and vomiting and visual disturbances. However, 10% of these patients may be asymptomatic.

Patients with brain mets have a mean survival of one month without treatment. With treatment, survival improves, but it is still dismal. The mean age of survival is still less than one year.

Differential Diagnosis

  • Abscess: typically hypermetabolic with central hypometabolism signifying necrosis
  • CVA
  • Primary brain neoplasm
  • Meningioma
  • Post-treatment effects (post-surgical or post radiation): hypermetabolic acutely progressing to hypometabolic over time
  • Epilepsy

Image Gallery for Differential Diagnosis

Treatment

Symptomatic: Corticosteroids are given to limit the effects of peritumoral edema. Hyperosmolar agents (eg mannitol) can be given to decrease ICP and anticonvulsants are given to prevent seizures. Recently, methylphenidate and donepezil have been used to improve cognition, mood and quality of life.

Therapeutic: Radiation (whole brain external beam or stereotactic for smaller masses), chemotherapy and surgical resection are done to prolong survival and palliate symptoms. Other than germ cell tumours, leukemias and lymphomas, palliation is the rule and curative therapy is the subject of case reports.


Template:SIB


Template:WikiDoc Sources